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Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer, with more than 450,000 newly diagnosed cases worldwide every year (1) . HNSCC causes significant morbidity and mortality, with a 5-year survival rate of <50%, and it has remained relatively unchanged for the past three decades (2) . HNSCC progression involves the sequential acquisition of genetic and epigenetic alterations in tumor suppressor genes and oncogenes (3) . Among the multiple molecular mechanisms that are dysregulated in HNSCC, accumulating evidence demonstrates the importance of Akt/mTOR signaling in HNSCC progression (4) . Activation of Akt and its downstream target molecule, mTOR, has been observed in more than 80% of HNSCC lesions (5) . The activation of mTOR can be the result of enhanced expression and activity of the epithelial growth factor receptor (5) , mainly because of the presence of activating mutations in the catalytic subunit of phosphoinositide-3-kinase (PI3K), or from the decreased expression of the PIP3 phosphatase PTEN (Phosphatase and Tensin homolog). Phosphorylation of mTOR activates key eukaryotic translation regulators, including p70-S6 kinase (p70S6K, which directly targets ribosomal S6 protein) and the eukaryotic translation initiation factor 4-E binding protein 1 (4E-BP1). The latter prevents the repressing activity of 4E-BP1 on the eukaryotic initiation factor 4E (eIF4E) (6) , ultimately resulting in enhanced translation from a subset of genes that are required for cell growth of HNSCC (4) .
Activation of mTOR is an early event in HNSCC, as well as one of the most frequent, and it is also related to lymph node metastasis (5, 7) . eIF4E-positive surgical margins have more than a 6-fold risk of developing local recurrences (8) . Moreover, inhibition of the mTOR activity complex 1 (mTORC1) by specific inhibitors such as Rapamycin (sirolimus) has been shown to induce a rapid regression and prevent recurrence of these tumors in a xenograft mouse model (9) . It has also decreased tumor burden and the malignant conversion of potential HNSCC precancerous lesions in genetically defined and chemically induced animal models of HNSCC (10) . Survivin, a member of the mammalian inhibitor of apoptosis (IAP), is also regulated by Akt and mTOR (11) . Overexpression of survivin often correlates with poor prognosis of HNSCC (12) .
We previously reported that the deletion of transforming growth factor-β receptor I (Tgfbr1) promotes tumorigenesis of HNSCC mainly through activation of Akt, but does not initiate it (13) . In addition, compound deletions of Tgfbr1 and Pten in oral mucosa resulted in spontaneous development of HNSCC with 100% penetrance (14) . These observations prompted us to examine whether Tgfbr1-mediated signaling could regulate the activity of mTOR and survivin expression in Tgfbr1/Pten double conditional knock out (2cKO) mice. Additionally, we also examined the effects of an mTOR inhibitor on tumorigenesis of HNSCC in our mouse model. We report here that the activation of mTOR with survivin is a widespread event in spontaneously developed HNSCC of Tgfbr1/Pten 2cKO mice, and that Rapamycin treatment delayed tumorigenesis of HNSCC by inhibiting activation of mTOR and survivin, resulting in prolonged survival. Laboratories and maintained as previously described (13, 14) . The Tgfbr1/Pten 2cKO mice and the Pten cKO mice and their controls were from the same litter and therefore had the same mixed genetic background of C57BL/6; FVBN; CD1; 129. All animal studies were conducted in accordance with the NIH guidelines for the Care and Use of Laboratory Animals and approved by IACUC, NIDCR. The tamoxifen treatment procedure has been previously described (13, 14) . Mice were housed in appropriate sterile filter-capped cages, and fed and watered ad libitum. Only 4-to 8-week-old male and female Tgfbr1/Pten 2cKO mice were included in this study.
Materials and Methods

Generation of
Rapamycin treatment
Rapamycin was initially dissolved in 100% ethanol at a concentration of 50 mg/ml, and stored at -20°C. The working solution was further diluted in an aqueous phase of 5.2% Tween 80 and 5.2%
polyethylene glycol 400 and prepared immediately before use. For the chemopreventive tumorigenesis studies, 4-weeks after the last oral dose of tamoxifen the mice were randomized into a control group (n = 17 mice) or a group that received 10 mg/kg Rapamycin i.p. every other day (n =17 mice). Mice were treated with this dosing schedule of Rapamycin for 6 weeks, and tumor size was measured weekly. Tumor volume was calculated by multiplying the three dimensions of each tumor using a micrometer caliper. Tumor burden was calculated as the individual tumor volume in each mouse and normalized with relative tumor growth by dividing the final volume by the initial tumor volume. At the end of the tumorigenesis studies, mice were euthanized using CO 2 and tumor, lung, and liver tissues were harvested and then fixed in Z-fix overnight and cut into 5um-thick sections. For the chemopreventive survival studies, mice were treated either with vehicle or 10mg/kg Rapamycin every other day for 4 weeks, beginning 2 weeks after the last dose of tamoxifen (n =15 mice from control group and n=14 in Rapamycin group). The mice were euthanized when they reached a humane endpoint (when tumors reached 2 cm in size or when mice were distressed by the tumor burden) that was confirmed independently by a veterinarian. For the chemotherapeutic studies, 4 weeks after the last dose of oral tamoxifen the mice were randomized into a control group (n = 9 mice) or a group that received 10 mg/kg Rapamycin i.p. every other day (n =11 mice) for 1 week, based on our pilot study on the tumorigenesis and survival of 2cKO mice. At the end of the chemotherapeutic studies, mice were euthanized using CO 2 , fixed in Z-fix overnight, and processed for histology.
Cell culture and RNA interference
HNSCC cell lines CAL27（ATCC, Manassas, VA） and HSC3 were maintained in Dulbecco's modified Eagle's medium (DMEM)/F12, 10% fetal bovine serum, at 5% CO 2 and 37˚C in a humidified incubator as previously described (14) (15) . For functional analysis, non-targeting negative control siRNA (Qiagen, Valencia, CA), Pten siRNA, Tgfbr1 siRNA, and combined Pten/Tgfbr1 siRNA were transfected into the appropriate cells using Hiperfect transfection reagent (Qiagen) with a final concentration of 5nM (Supplementary Table 1 ). For inhibition efficiency and target mRNA transcription studies, RNA was extracted 24h after transfection. For protein extraction, cells were lysed 72h after transfection.
Histology and Immunohistochemistry
See Supplementary Material
Western blot analysis
See Supplementary Material
Human HNSCC tissues array
Tissue arrays of formalin-fixed tissues from human head and neck squamous cell carcinoma (HN803) were retrieved from Biomax US (Rockville, MD, USA). Clinical data, including pathological classification and TNM classification, were provided by Biomax. These tissue microarray slides included 57 confirmed cases of HNSCC, 10 cases of normal tongue mucosa, and 4 cases of lymph node metastasis in HNSCC tissue. Immunohistochemistry for Tgfbr1 (1:100), p-S6 (S235/236, 1:200), and Survivin (1:400) was stained in serial-cut tissue array sections.
Statistical analysis
Data analyses were performed using Graph Pad Prism version 5.00 for Windows (Graph-Pad Software Inc, La Jolla, CA). One-way ANOVA followed by the post-Turkey or Bonferroni multiple comparison tests were used to analyze the differences in immunostaining and protein levels among each group.
The Mann-Whitney U test was used to evaluate differences in the total tumor area of the mice treated with Rapamycin and of the untreated control group. Two-way ANOVA with Bonferroni post-test were used for the tumor burden of Rapamycin chemopreventive and chemotherapeutic experiments.
One-way ANOVA followed by Dunnett post-test were used to compare the vehicle and p-Akt, p-S6, and survivin levels, we hypothesized that Tgfbr1 deletion in Tgfbr1/Pten 2cKO mouse HNSCC tumors is responsible for the increase in p-Akt, p-S6, and survivin levels. Using Western blot analysis, we confirmed that there was a dramatic increase in phosphorylation of Akt, S6, and survivin in the 2cKO HNSCC (n=5, Supplementary Fig. 2A) , as compared to Pten cKO mice HNSCC (n=4, Supplementary Fig. 2A ). This was further confirmed by immunohistochemical staining for p-S6 S235/236 and survivin in the Tgfbr1/Pten 2cKO HNSCC and Pten cKO HNSCC ( Supplementary Figs. 2B and C). The data suggest that activation of mTOR by deletion of Pten is further compounded by the additional deletion of Tgfbr1, resulting in not only the activation of mTOR but also the activation of survivin and the acceleration of tumorigenesis in Tgfbr1/Pten 2cKO HNSCC.
Results
Knockdown of Tgfbr1 and
Decreased expression of Tgfbr1 is related to increase of survivin in human HNSCC tissues
In order to assess the correlation between Tgfbr1 expression and the survivin levels in human HNSCCs, we stained the tumor sections from human tissue arrays for HNSCC (n=57) with antibodies for Tgfbr1, p-S6, and survivin and compared them with normal head and neck mucosa samples (n=10).
Representative figures of Tgfbr1, survivin, and p-S6 immunostaining are shown in Fig. 3A . Tgfbr1 immunostaining reveals that Tgfbr1 is strongly stained in the cytoplasm and membrane of oral mucosa but that it is significantly decreased in 47.4% of HNSCC cores (Fig. 3A) , which is consistent with previous findings (14) . We also found that normal mucosa showed mild expression of S6 in the superficial layer but not the basal layer of the epithelium, which is consistent with previous reports (5).
Survivin staining was mainly observed in the cytoplasm and membrane of the normal epithelium 
tumorigenesis in Tgfbr1/Pten 2cKO mouse HNSCC. We induced Cre-mediated deletion of Tgfbr1 and Pten deletion by tamoxifen administration, and 2 weeks later we initiated treatment with Rapamycin, a potent inhibitor of mTOR (Fig. 4A) . Rapamycin treatment significantly delayed the progression of papilloma and the onset of squamous cell carcinoma in the head and neck region (Fig. 4B) as well as in the oral cavity (Fig. 4C) Rapamycin-treated group (n=11), as compared with the control group (n=9). Therefore, these data indicate that Rapamycin treatment results in significantly lower proliferation and increased apoptosis in these HNSCC tumors.
Discussion
A newly gained molecular understanding of HNSCC initiation and progression may soon present the opportunity to develop novel drug targets and therapeutic approaches. In this regard, among the multiple aberrant genetic, epigenetic, and signaling events known to occur in HNSCCs, the persistent activation of the Akt/mTOR pathway has emerged as a potential drug target for HNSCC treatment (5).
Recent preclinical investigations have indicated that the use of mTOR inhibitors, including
Rapamycin and its analogues, can significantly reduce tumor burden and even recurrence of HNSCC in animal models generated by different strategies such as tumor xenografts, carcinogen-induced tumors, and genetic engineering used to recapitulate initiation and progression of HNSCC (7, 9, 10, 16, 17) . Our in vitro data suggested that loss of Tgfbr1 activates Akt/mTOR/survivin expression in the human HNSCC cell lines. Furthermore, using a genetically engineered mouse model that spontaneously develops visible HNSCC tumors on the tongue and facial region with consistent full penetrance for conditional deletion of Pten and Tgfbr1, we now show that activation of the Akt/mTOR/survivin axis is the most significant molecular event caused by the deletion of Pten and Tgfbr1. Inhibition of mTOR with Rapamycin can reduce tumoral growth in the head and neck region as well as in the tongue, thereby prolonging animal survival.
Interestingly, we found that knockdown Tgfbr1 could activate phosphorylation of the Akt and mTOR pathways and increase survivin levels in vitro. In line with these observations, although survivin is known as a downstream target of mTOR (11), we noticed that the knockdown of Tgfbr1 increases survivin to a greater extent than knockdown of Pten. This finding is consistent with the previously reported independent finding that the loss of both Tgfbr1 and Tgfbr2 correlated with the increased survivin level (18) , and that TGFβ1 down-regulated survivin in prostate cancer through Rb/E2F4 and Smad2/3 pathways (19) . Even more interestingly, the knockdown of both Tgfbr1 and Pten increased survivin levels. Additionally, we observed significant activation of the Interestingly, this animal model is very sensitive to Rapamycin and tumor shrinkage was observed over the course of a week, which is not usually the case in mousce models for mTOR inhibition. On one hand, our observation suggests that deletion of both Tgfbr1 and Pten will activate mTOR. On the other hand, this result may in fact be due to the mouse model's intact immune system, and inhibition of mTOR may affect tumor microenvironments such as the immune system, chemokine, and angiogenesis (21, 22) . Our previous and present findings also suggest that there is a significant activation of the EGFR/PI3K/Akt axis, activation of the stat3 and IKKβ/NF-κB pathways, and overexpression of VEGFA and cylcin D1 in this mouse model, all of which are important molecular events amenable for mTOR inhibition (25) . Although Tgfbr1 gene mutation may not be a significant factor in HNSCC (26, 27) , the reports on tumor-susceptible polymorphism resulting in hypofunction of TGFBR1 should not been ignored (28, 29) . Indeed, we found that almost 40% of HNSCC patients have concurrent low protein levels of Tgfbr1 and Pten (14) , and therefore this genetically manipulated mouse model may not fully reflect the clinical spectrum of human HNSCC. While keeping this potential limitation in mind, this mouse model has revealed a potent anticancer function of mTOR inhibitors, which could have multiple beneficial implications for treating HNSCC patients.
The inhibition of mTOR in experimental and clinical HNSCC lesions leads to a rapid decrease in the phosphorylated state of S6, a downstream target of mTORC1 (20) that also serves as a biomarker for the molecular response to mTOR inhibitors in their target tissues. In 2cKO mouse HNSCCs, Rapamycin also causes a rapid decrease in the phosphorylation of Akt at serine 473, a downstream target of mTORC2 (9, 10, 17) , suggesting a sensitivity to Rapamycin (25) . As shown in the human HNSCC xenograft animal model (7), our data also suggested that inhibition of mTOR significantly decreases expression of survivin and cyclin D1, inhibits proliferation, and promotes apoptosis in this mouse HNSCC. This effect could contribute to the antitumor activity of Rapamycin. Thus, the inhibition of mTORC1 in mouse HNSCCs may result in a reduced cell cycle and may induce apoptosis.
Research. 
Among the risk factors influencing a patient's outcome, the presence of an increase in survivin levels and active Akt/mTOR signaling at the time of diagnosis represents the most important factor predicting a poor prognosis (3, 12, 30, 31) . Unfortunately, high expression of survivin is often accompanied by early metastatic disease and recurrence (12) . In this regard, the emerging preclinical and clinical information about the promising beneficial effects of mTOR inhibitors in HNSCCs, together with our present findings, demonstrate a potentially successful outcome of such therapy for the HNSCC patients. We believe that the Tgfbr1/Pten 2cKO mice provide a good animal model for preclinical evaluations of Akt/mTOR and survivin inhibitors, as part of targeted strategies for chemopreventive and chemotherapeutics treatment of HNSCC.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed. 
Figure Legends
